Immune Tolerance Clinical Trial
Official title:
Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-Cell Transfusion in HLA-Matched Living Donor Kidney Transplantation
The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone Marrow Transplantation are enrolling patients into a research study to determine if blood stem cells injected after kidney transplantation, in combination with lymphoid irradiation ,will change the immune system such that immunosuppressive drugs can be completely withdrawn. Patients must have a healthy, completely human leukocyte antigen (HLA)-matched brother or sister as the organ and stem cell donor. One to two months before kidney transplant surgery, blood stem cells will be removed from the donor and the cells will be frozen. After transplant surgery, the recipient will receive radiation and anti-T cell antibody treatments for two weeks to prepare for injection of the stem cells. The stem cells will be injected at the end of the two-week treatment. If the stem cells persist in the recipient, immunosuppressive drugs will be gradually reduced until they are withdrawn completely at least six months after transplantation. Patients will be followed in the Stanford clinics for transplant patients. Patients who live outside of the San Francisco Bay Area must remain near Stanford for six weeks after transplant surgery.
The purpose of this study is to determine the proportion of patients that can be withdrawn completely from immunosuppressive drugs while maintaining normal function of HLA-matched living related donor kidney transplants. Fifteen participants will be conditioned with total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (ATG), and given an infusion of donor "mobilized" blood mononuclear cells prior to transplantation. This is a single-center, open-label study in adult renal transplant patients. Fifteen patients will receive TLI, ATG, and an infusion of CD34+ selected G-CSF mobilized blood cells combined with a fixed number (1x10^6) of CD3+ T cells from the same mobilized blood cell source. Patients will receive a one-month course of mycophenolate mofetil and a six to 12 month tapering course of cyclosporine that will be discontinued at six months. At serial timepoints (1) graft function will be monitored, (2) chimerism will be measured in recipient white blood cell subsets, (3) mixed lymphocyte response (MLR) assays of peripheral blood mononuclear cells against donor and third party cells will be performed, and (4) protocol biopsies of the graft will be obtained. An attempt will be made to discontinue cyclosporine at six months if (1) chimerism is detectable for at least 180 days after CD34+ and CD3+ cell infusion, (2) there is stable graft function without clinical rejection episodes, and (3) there is lack of histologic rejection on protocol biopsies. In the proposed study, patients will be given a target dose of 8-10x10^6 CD34+ cells/kg and 1x10^6 CD3+ cells/kg because sustained chimerism may be necessary for sustained tolerance to the graft. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04621916 -
Preventing Inhibitor Recurrence Indefinitely
|
Phase 4 | |
Recruiting |
NCT06243289 -
Improving KIdney Transplantation With Cellular Therapy Study
|
||
Recruiting |
NCT03591302 -
Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs.
|
Phase 1 | |
Completed |
NCT04525456 -
Immune Responses With Reduxium
|
N/A | |
Recruiting |
NCT04314518 -
The Correlation Between Immunological Reaction of the Seminal Fluid in the Mother's Blood and Pregnancy Complications
|
||
Enrolling by invitation |
NCT04571203 -
Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment
|
Phase 1 | |
Recruiting |
NCT01367821 -
Immune Function in Patients With Obstructive Jaundice
|
N/A | |
Enrolling by invitation |
NCT01117077 -
The Immune Tolerance Mechanism Induced by IL-17-producing Regulatory T Cells in the Orthotopic Liver Transplant Recipients With Aspergillosis
|
N/A | |
Terminated |
NCT05010174 -
Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
|
||
Active, not recruiting |
NCT03744325 -
Immune Responses in Hen's Egg Oral Immunotherapy
|
N/A | |
Completed |
NCT03383211 -
Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
|
||
Recruiting |
NCT02861872 -
Intra-peritoneal Chemotherapy in Ovarian Cancer
|
N/A | |
Completed |
NCT01538485 -
Vitamin D Supplementation and Regulatory FoxP3+ T Cells in the GUT
|
Phase 4 | |
Completed |
NCT03393793 -
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
|
||
Completed |
NCT01996774 -
Immunologic Profile of Children With Severe Allergies to Peanuts and Nuts After Induction of Tolerance
|
N/A | |
Recruiting |
NCT03292445 -
Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation
|
Early Phase 1 | |
Active, not recruiting |
NCT05745792 -
Clinico-immunological Characterization and Immune Tolerance Breakdown in HU-autoimmunity
|
||
Completed |
NCT02642237 -
The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response
|
N/A | |
Completed |
NCT01414504 -
Pneumococcal Conjugate Vaccine Followup
|
Phase 2 | |
Not yet recruiting |
NCT06147375 -
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation
|
N/A |